Mechanistic insights into improved cardiac function, reduced ventricular pressures, enhanced exercise tolerance, and reduced sympathetic activity were observed in the empagliflozin group, contributing to a deeper understanding of SGLT2 inhibitors’ effects on heart failure pathophysiology. The gene discussed is SLC5A2; the disease is heart failure.